secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001447362-24-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences expects 2023 revenue >$210M, exceeding guidance; test volume +59%
--------------------------------------------------------------------------------

- Expects 2023 total revenue >$210M, at least 53% growth over 2022, surpassing prior guidance floor of $200M.
- Delivered 70,429 total test reports in 2023, up 59% YoY; Q4 reports 20,284, up 60% YoY.
- TissueCypher Barrett's Esophagus test reports surged 328% YoY in 2023; IDgenetix up 236%.
- Year-end cash, equivalents and short-term investments expected ~$243M.
- Preliminary results, subject to audit completion; final results may differ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736224000006/0001447362-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736224000006/cstl-20240107.htm
  HTML page:      https://secwatch.observer/filing/0001447362-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer